版本:
中国

BRIEF-Novo Nordisk says Tresiba showed significant reduction in rates of severe hypoglycaemia compared to insulin glargine

June 12 Novo Nordisk A/S:

* tresiba showed no increased risk of major cardiovascular events and significant reduction in rates of severe hypoglycaemia compared to insulin glargine

* Novo Nordisk says trial demonstrated that tresiba met primary endpoint of non-inferiority compared with insulin glargine u100 for major adverse cv events

* results from secondary endpoints of trial showed significant reduction in rate of severe and nocturnal severe hypoglycaemia with tresiba versus insulin glargine u100

* Novo Nordisk says safety profile of tresiba in devote was generally consistent with previous tresiba clinical trial Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐